tiprankstipranks
Advertisement
Advertisement

SE:ONCO Stock Latest News

Oncopeptides Boosts Share Capital After Rights Issue to Support Cancer Drug Push
Company AnnouncementsOncopeptides Boosts Share Capital After Rights Issue to Support Cancer Drug Push
12d ago
Oncopeptides Raises SEK 190 Million in Partially Guaranteed Rights Issue
PremiumCompany Announcements
Oncopeptides Raises SEK 190 Million in Partially Guaranteed Rights Issue
25d ago
Oncopeptides Launches Real-World MARINA Study for Pepaxti in Germany
PremiumCompany Announcements
Oncopeptides Launches Real-World MARINA Study for Pepaxti in Germany
27d ago
Real-World Data Bolsters Oncopeptides’ Pepaxti as Bridging Therapy in Multiple Myeloma
PremiumCompany Announcements
Real-World Data Bolsters Oncopeptides’ Pepaxti as Bridging Therapy in Multiple Myeloma
30d ago
Oncopeptides Wins Fast-Track Status for First PDC Trial in Glioblastoma
PremiumCompany Announcements
Oncopeptides Wins Fast-Track Status for First PDC Trial in Glioblastoma
1M ago
Oncopeptides AB Balances Growth, Cash Crunch in Earnings
PremiumCompany AnnouncementsOncopeptides AB Balances Growth, Cash Crunch in Earnings
2M ago
Oncopeptides launches SEK 200m rights issue to fund Pepaxti rollout and glioblastoma push
Premium
Company Announcements
Oncopeptides launches SEK 200m rights issue to fund Pepaxti rollout and glioblastoma push
2M ago
Oncopeptides Doubles 2025 Sales and Raises Capital to Drive Glioblastoma Push
Premium
Company Announcements
Oncopeptides Doubles 2025 Sales and Raises Capital to Drive Glioblastoma Push
2M ago
Oncopeptides Sets Date for 2025 Year-End Results Presentation
PremiumCompany Announcements
Oncopeptides Sets Date for 2025 Year-End Results Presentation
2M ago
Oncopeptides Lifts 2025 Sales but Delays Cash-Flow Break-Even to 2027
PremiumCompany Announcements
Oncopeptides Lifts 2025 Sales but Delays Cash-Flow Break-Even to 2027
3M ago
Oncopeptides Drug Pepaxti Shows Strong Efficacy in High-Risk Multiple Myeloma
PremiumCompany Announcements
Oncopeptides Drug Pepaxti Shows Strong Efficacy in High-Risk Multiple Myeloma
3M ago
Oncopeptides AB Establishes Nomination Committee for 2026 AGM
PremiumCompany Announcements
Oncopeptides AB Establishes Nomination Committee for 2026 AGM
5M ago
Expert Panel Endorses Oncopeptides’ Pepaxti for Myeloma Treatment
PremiumCompany AnnouncementsExpert Panel Endorses Oncopeptides’ Pepaxti for Myeloma Treatment
5M ago
Oncopeptides AB Earnings Call Highlights Growth and Challenges
Premium
Company Announcements
Oncopeptides AB Earnings Call Highlights Growth and Challenges
5M ago
Oncopeptides AB Reports Strong Q3 2025 Growth and Strategic Milestones
Premium
Company Announcements
Oncopeptides AB Reports Strong Q3 2025 Growth and Strategic Milestones
5M ago
Oncopeptides’ NK Cell Engager Study to be Presented at ASH
PremiumCompany Announcements
Oncopeptides’ NK Cell Engager Study to be Presented at ASH
5M ago
Oncopeptides Adjusts Share Structure Amid Strategic Incentive Program
PremiumCompany Announcements
Oncopeptides Adjusts Share Structure Amid Strategic Incentive Program
5M ago
Oncopeptides to Release Q3 2025 Financial Report
PremiumCompany Announcements
Oncopeptides to Release Q3 2025 Financial Report
5M ago
Oncopeptides to Host Strategic Capital Markets Update
PremiumCompany Announcements
Oncopeptides to Host Strategic Capital Markets Update
6M ago
Oncopeptides’ Pepaxti Shows Promising Long-term Results in Myeloma Treatment
PremiumCompany AnnouncementsOncopeptides’ Pepaxti Shows Promising Long-term Results in Myeloma Treatment
6M ago
Oncopeptides Issues Warrants to Meet EIB Loan Obligations
Premium
Company Announcements
Oncopeptides Issues Warrants to Meet EIB Loan Obligations
6M ago
Oncopeptides AB Announces Share and Vote Changes Post Rights Issue
Premium
Company Announcements
Oncopeptides AB Announces Share and Vote Changes Post Rights Issue
6M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >